Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7047591rdf:typepubmed:Citationlld:pubmed
pubmed-article:7047591lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0001622lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0311400lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0243161lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0332237lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0149783lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C1522168lld:lifeskim
pubmed-article:7047591lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:7047591pubmed:issue6lld:pubmed
pubmed-article:7047591pubmed:dateCreated1982-9-24lld:pubmed
pubmed-article:7047591pubmed:abstractTextSystemic absorption of topically applied glucocorticoids in quantities sufficient to replace endogenous production is not uncommon. However, iatrogenic Cushing's syndrome resulting from the use of topical corticosteroids is very rare. Thus the possibility that systemic absorption may cause hyperglucocorticism has been deemphasized and examined only sporadically. We have studied changes in carbohydrate metabolism induced by topical glucocorticoids in a psoriatic patient who had developed Cushing's syndrome from topical desoximetasone (Topicort). The results indicated that (1) fasting hyperglycemia and increased insulin-glucose ratios could be induced within 24 hours of administration of topical glucocorticoids, (2) insulin resistance accompanied abnormal carbohydrate tolerance, and (3) fluctuations in circulating leukocytes paralleled the changes in carbohydrate metabolism. The findings suggest that metabolic indexes of glucocorticoid action action may provide useful parameters for assessing systemic absorption of topical glucocorticoids. glucose relationship as one such index to assess the risk of treatment of extensive chronic skin disease with potent topical glucocorticoids.lld:pubmed
pubmed-article:7047591pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:languageenglld:pubmed
pubmed-article:7047591pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:citationSubsetIMlld:pubmed
pubmed-article:7047591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7047591pubmed:statusMEDLINElld:pubmed
pubmed-article:7047591pubmed:monthJunlld:pubmed
pubmed-article:7047591pubmed:issn0190-9622lld:pubmed
pubmed-article:7047591pubmed:authorpubmed-author:LevinD LDLlld:pubmed
pubmed-article:7047591pubmed:authorpubmed-author:CookL JLJlld:pubmed
pubmed-article:7047591pubmed:authorpubmed-author:ZugermanCClld:pubmed
pubmed-article:7047591pubmed:authorpubmed-author:FreinkelR KRKlld:pubmed
pubmed-article:7047591pubmed:authorpubmed-author:RadtkeRRlld:pubmed
pubmed-article:7047591pubmed:issnTypePrintlld:pubmed
pubmed-article:7047591pubmed:volume6lld:pubmed
pubmed-article:7047591pubmed:ownerNLMlld:pubmed
pubmed-article:7047591pubmed:authorsCompleteYlld:pubmed
pubmed-article:7047591pubmed:pagination1054-60lld:pubmed
pubmed-article:7047591pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:meshHeadingpubmed-meshheading:7047591-...lld:pubmed
pubmed-article:7047591pubmed:year1982lld:pubmed
pubmed-article:7047591pubmed:articleTitleIatrogenic hyperadrenocorticism during topical steroid therapy: assessment of systemic effects by metabolic criteria.lld:pubmed
pubmed-article:7047591pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7047591pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:7047591pubmed:publicationTypeCase Reportslld:pubmed